Salt Lake City-based ARUP Laboratories has released a combined test to detect and differentiate COVID-19, influenza or respiratory syncytial virus (RSV) in individuals with respiratory symptoms consistent with COVID-19. The test is designed to allow symptom sufferers to know which of the three is causing their illness.
The test is the first offered in the United States and was developed using Thermo Fisher Scientific’s TaqMan SARS-CoV-2, Flu A/B, RSV multiplex tests and runs on the QuantStudio Real-Time Polymerase Chain Reaction (PCR) platform.
“We are proud to offer this test, which is one of the first available to test for all four viruses,” said Adam Barker, director of ARUP’s COVID Rapid Response Laboratory. “This single test is a simple, accurate way to determine which virus is the cause of illness as the flu and RSV seasons get underway amid the COVID pandemic.”
ARUP’s test detects ribonucleic acid (RNA) from SARS-CoV-2, the virus that causes COVID, along with the influenza A and B viruses and RSV. A qualitative test, it also differentiates between the viruses, although it does not differentiate between influenza A and B.
The test can be performed on specimens collected using a deep nasal swab or on specimens collected from the back of the throat and the front of both nostrils.
The test adds to ARUP’s menu of COVID-related tests, which includes a molecular diagnostic test for COVID that can be performed on multiple specimen types, including saliva.
ARUP also offers two IgG antibody tests to detect previous exposure to SARS-CoV-2, along with numerous tests that help guide treatment of patients with the virus.
“The challenge clinicians face as we enter flu season is unparalleled even if flu and RSV activity remain low,” said ARUP CEO Dr. Sherrie L. Perkins. “We’re pleased that this combination test will help them provide the best patient care possible as the pandemic persists.”
